Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. SK Biopharmaceuticals Co., Ltd.
  6. News
  7. Summary
    A326030   KR7326030004

SK BIOPHARMACEUTICALS CO., LTD.

(A326030)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SK Biopharmaceuticals Narrows Loss in Q3

11/12/2021 | 05:36am EST


ę MT Newswires 2021
All news about SK BIOPHARMACEUTICALS CO., LTD.
01/04BIORCHESTRA and SK Biopharmaceuticals Collaborate to Develop Mirna-Targeted Therapeutic..
CI
2021Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPR..
AQ
2021Health Care Stocks Advance Premarket Thursday
MT
2021Endo International Signs Agreement to Commercialize SK Biopharmaceuticals' Cenobamate i..
MT
2021SK Biopharmaceuticals Narrows Loss in Q3
MT
2021SK Biopharmaceuticals' New Drugs Draw Favorable Reception in North America, Europe
MT
2021KOSPI COMPOSITE INDEX : South Korean Stocks Fall for a Second Straight Session; SK Biophar..
MT
2021KOSPI COMPOSITE INDEX : South Korean Stocks Close in Green on Foreign Buying Ahead of US L..
MT
2021MARKET CHATTER : SK Biopharmaceuticals Launches Epilepsy Drug in Europe
MT
2021SK Biopharmaceuticals Co., Ltd. Reports Consolidated Earnings Results for the First Qua..
CI
More news
Financials
Sales 2021 235 B 0,20 B 0,20 B
Net income 2021 -12,2 B -0,01 B -0,01 B
Net cash 2021 284 B 0,24 B 0,24 B
P/E ratio 2021 -608x
Yield 2021 -
Capitalization 6 860 B 5 765 M 5 756 M
EV / Sales 2021 28,0x
EV / Sales 2022 19,2x
Nbr of Employees -
Free-Float -
Chart SK BIOPHARMACEUTICALS CO., LTD.
Duration : Period :
SK Biopharmaceuticals Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SK BIOPHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 87 600,00 KRW
Average target price 133 285,71 KRW
Spread / Average Target 52,2%
EPS Revisions
Managers and Directors
Jeong-Woo Cho President, Chief Executive Officer & Director
Young-Ju Bang Independent Director
Hae-Young Ahn Independent Director
Min-Seop Song Independent Director
Geun-Joo Hwang Non-Executive Director
Sector and Competitors